In Virtual reality news
August 4, 2021 – Ketamine One Capital Limited, a company focused on consolidating medical clinics and providing mental health treatments, announced today that it has signed an exclusive agreement for the use of virtual reality (VR) technology in psychedelic treatments with OVR technology provide their “INHALE wellness platform” for an initial two-year period at Ketamine One clinics.
As part of the agreement, OVR Technology will provide its proprietary technology and services so that Ketamine One can use them with its psychedelic-assisted treatments involving ketamine, psilocybin, DMT and MDMA in order to help improve patient outcomes.
OVR Technology’s INHALE wellness platform is an olfactory virtual reality platform designed to deepen immersion, promote relaxation and help control stress. The platform is designed to combine the benefits of mindfulness, breathing work and meditation with the next generation of aromatherapy. It includes a head-mounted screen, the “ION” device and odor cartridges, as well as various nature scenes focused on odor. The ION is lightweight, wireless, and emits scented particles in coordination with VR technology designed to deepen a patient’s immersive experience.
OVR Technology’s “Architecture of Scent” platform brings together software, “Scentware” and hardware via ION, while including replaceable cartridges and an olfactory experience engine that allows you to activate the smell during a reality experience virtual. The perfumes delivered through the ION are water-based and are made from a combination of natural and synthetic ingredients that have been extensively tested, according to the company. While VR technology is known to incorporate vision and sound, this partnership will provide Ketamine One with the ability to generate more realistic immersive VR service offerings through scents in its network of clinics, which the company hopes will enhance experiences and help improve patient outcomes. .
“We believe the ION device contains the most accurate mask odor technology currently available on the market.” said Dr. Quang Henderson, chairman of the Innovation Council of the Ketamine One Clinic. “The ability of our doctors to alter perceptual experiences with VR and ION is extremely promising. The optimization of the therapeutic environment is one of the main objectives of our research and development program based on virtual reality and to be able to use the sense of smell to help patients relax, reduce stress and decrease stress, will result in the development of a comprehensive treatment. ”
Adam Deffett, interim CEO of Ketamine One, added: “Our access to a large patient population and our enhanced research capabilities through our wholly owned contractual research organization, KGK Science, together with the OVR Technology’s innovative platform, combine the potential of leading to clinically validated solutions for use not only in our facilities but also in patients ’homes, by developing a portable digital therapeutic offering in the future ”.
Ketamine One noted that research has shown that odors cause emotional and evocative associations and can immediately alter mood.1 Other research shows that as soon as the brain registers an odor, it activates the amygdala-hippocampus complex in the limbic system where emotions, memories, and associations are processed, almost instantaneously.2
“This is the first virtual reality platform that understands the behavior of users in the virtual world and that responds with sensory stimulation in real time. It has the potential to significantly enhance the well-being capabilities of an already promising technology, ”said Aaron Wisniewski, CEO and co-founder of OVR Technology.
Founded in 2017, OVR Technology is one of the companies developing solutions based on olfactory (sense of smell) for virtual reality, augmented reality and other digital environments. For more information on OVR technology, visit the company website.
Image credit: OVR Technology / Ketamine One
1 Herz, 1998; 2009; Herz et al., 2004; Larsson et al., 2014.
2 Cor, 2020.